NO752586L - - Google Patents
Info
- Publication number
- NO752586L NO752586L NO752586A NO752586A NO752586L NO 752586 L NO752586 L NO 752586L NO 752586 A NO752586 A NO 752586A NO 752586 A NO752586 A NO 752586A NO 752586 L NO752586 L NO 752586L
- Authority
- NO
- Norway
- Prior art keywords
- soluble
- carbon atoms
- group
- melting point
- insoluble
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 238000002844 melting Methods 0.000 description 12
- 230000008018 melting Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 9
- 239000000843 powder Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 5
- 230000002048 spasmolytic effect Effects 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000000794 anti-serotonin Effects 0.000 description 4
- 239000003420 antiserotonin agent Substances 0.000 description 4
- 208000005392 Spasm Diseases 0.000 description 3
- 230000003474 anti-emetic effect Effects 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 230000000701 neuroleptic effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- MRBFGEHILMYPTF-UHFFFAOYSA-N 1-(2-Pyrimidyl)piperazine Chemical class C1CNCCN1C1=NC=CC=N1 MRBFGEHILMYPTF-UHFFFAOYSA-N 0.000 description 1
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000009132 Catalepsy Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- VTBFSWZDBXKKJU-UHFFFAOYSA-N ClO.N1=CN=CC=C1 Chemical compound ClO.N1=CN=CC=C1 VTBFSWZDBXKKJU-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- -1 aromatic radical Chemical class 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000003170 musculotropic effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000723 toxicological property Toxicity 0.000 description 1
- 238000012345 traction test Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7427671A FR2281117A2 (fr) | 1974-08-09 | 1974-08-09 | Nouvelles piperazino-pyrimidines utilisables comme medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO752586L true NO752586L (enrdf_load_stackoverflow) | 1976-02-10 |
Family
ID=9142279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO752586A NO752586L (enrdf_load_stackoverflow) | 1974-08-09 | 1975-07-21 |
Country Status (13)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2417507A2 (fr) * | 1977-07-28 | 1979-09-14 | Ugine Kuhlmann | Diamino-2,4 (ou -4,6) methylthio-5 pyrimidines herbicides |
| FR2503162A1 (fr) * | 1981-04-07 | 1982-10-08 | Pharmindustrie | Nouveaux derives de piperazino-2 pyrimidine, procedes pour leur preparation et leur utilisation comme medicaments ou comme intermediaires pour la fabrication de medicaments |
| JPS5973573A (ja) * | 1982-09-09 | 1984-04-25 | ワ−ナ−−ランバ−ト・コンパニ− | ジアミノピリミジン化合物 |
| US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| PE20051029A1 (es) | 2003-07-02 | 2005-12-07 | Vertex Pharma | Pirimidinas moduladoras de canales ionicos regulados por voltaje |
| WO2006130493A2 (en) | 2005-05-31 | 2006-12-07 | Vertex Pharmaceuticals Incorporated | Heterocycles useful as modulators of ion channels |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2119234A5 (en) * | 1970-12-24 | 1972-08-04 | Ugine Kuhlmann | 5-alkylthio amino halopyrimidines - fungicides herbicides insecticides and bactericides |
| FR2173746B1 (enrdf_load_stackoverflow) * | 1972-03-01 | 1975-04-25 | Ugine Kuhlmann |
-
1974
- 1974-08-09 FR FR7427671A patent/FR2281117A2/fr active Granted
-
1975
- 1975-01-01 AR AR259942A patent/AR205579A1/es active
- 1975-07-21 NO NO752586A patent/NO752586L/no unknown
- 1975-08-01 NL NL7509184A patent/NL7509184A/xx not_active Application Discontinuation
- 1975-08-05 DE DE19752534963 patent/DE2534963A1/de not_active Withdrawn
- 1975-08-07 LU LU73175A patent/LU73175A1/xx unknown
- 1975-08-08 BE BE159072A patent/BE832277R/xx not_active IP Right Cessation
- 1975-08-08 GB GB33132/75A patent/GB1512101A/en not_active Expired
- 1975-08-08 ZA ZA00755118A patent/ZA755118B/xx unknown
- 1975-08-08 JP JP50096602A patent/JPS51125089A/ja active Pending
- 1975-08-08 ES ES440153A patent/ES440153A2/es not_active Expired
- 1975-08-08 CA CA233,149A patent/CA1036598A/fr not_active Expired
- 1975-08-11 CH CH1044275A patent/CH609692A5/xx not_active IP Right Cessation
-
1983
- 1983-02-04 JP JP58017292A patent/JPS5946943B2/ja not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| CH609692A5 (en) | 1979-03-15 |
| NL7509184A (nl) | 1976-02-11 |
| GB1512101A (en) | 1978-05-24 |
| LU73175A1 (enrdf_load_stackoverflow) | 1976-03-02 |
| FR2281117A2 (fr) | 1976-03-05 |
| ZA755118B (en) | 1976-07-28 |
| JPS5946943B2 (ja) | 1984-11-15 |
| CA1036598A (fr) | 1978-08-15 |
| JPS51125089A (en) | 1976-11-01 |
| ES440153A2 (es) | 1977-07-01 |
| DE2534963A1 (de) | 1976-02-19 |
| FR2281117B2 (enrdf_load_stackoverflow) | 1978-07-28 |
| AR205579A1 (es) | 1976-05-14 |
| BE832277R (fr) | 1976-02-09 |
| JPS58150571A (ja) | 1983-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3669968A (en) | Trialkoxy quinazolines | |
| US5352703A (en) | Antitussive and mucus regulating agent, a process for the preparation thereof and pharmaceutical compositions containing it | |
| GB2087883A (en) | Improvements in or relating to 3--aryloxy-3-phenylpropylamines | |
| KR890005105A (ko) | 벤즈이미다졸린-2-옥소-1-카복실산 유도체 | |
| US4971969A (en) | Pharmaceutical composition containing 1-(mono- or bis(trifluoromethyl)-2-pyridinyl)piperazines | |
| DD216934A5 (de) | Verfahren zur herstellung neuer derivate von xanthinen | |
| DE3779825T2 (de) | Derivate von benzhydryloxyaethylpiperazinen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| JPH01501226A (ja) | 化学療法剤によってひきおこされた▲おう▼吐のコントロール方法およびそれに有用な鎮吐薬 | |
| IE44739B1 (en) | Adenine derivatives | |
| NO752586L (enrdf_load_stackoverflow) | ||
| KR890005036A (ko) | 아미드화합물, 이들의 제조방법 및 이들 화합물을 함유하여 위신경기능을 활성화하는 조성물 | |
| KR880002705B1 (ko) | 치환된 2-페닐-2-(피리딜옥시)-에틸아민, 그의 등배전자 화합물 및 그의 산부가염의 제조방법 | |
| DE2461802A1 (de) | Pyrazinderivate | |
| DE3216843C2 (de) | 3-Thiomethyl-pyridin-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| US4083985A (en) | 6-Oxa-1-aza tricyclo dodecan-5-ones as psychomotor stimulators | |
| US5229392A (en) | 2-aminopyrimidine-4-carboxamide derivatives, their preparaton and their application in therapy | |
| WO2005092866B1 (en) | New derivatives of 4, 5, 6, 7-tetrabromobenzimidazole and method of their preparation | |
| JPS6140268A (ja) | イミダゾリン、その付加塩及びその製造方法並びにイミダゾリン又はその付加塩を有効成分とする医薬 | |
| US4588725A (en) | 2-piperazinyl-quinazoline derivatives and pharmaceutical compositions containing them | |
| AU2017204652B2 (en) | Treatment of Type I and Type II diabetes | |
| KR900003301B1 (ko) | 2-피페라지닐-4-페닐 퀴나졸린 유도체 및 그의 산염의 제조 방법 | |
| SU1187723A3 (ru) | Способ получени гидрохлорида 2-оксиметил- 6 -метил- 4- @ - толилтиено/2,3 - @ / пиперидина | |
| PT99299A (pt) | Processo de preparacao de esteres de piperidino-4-ol n-substituidos e de composicoes farmaceuticas que os contem | |
| DE69623602T2 (de) | Arginnin analoge mit no- syntax inhibierenderwirkung | |
| US4924008A (en) | Benzobicycloalkane derivatives as anticonvulsant neuroprotective agents |